Drugs / CKD-504
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03713892 | May 2018 → Dec 2020 | Huntington disease | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03713892 ↗ |
| Route | Oral | “orally administered once with investigational drug assigned on 1d morning with 240 mL of water” NCT03713892 ↗ |